Respiratory complex II defect in siblings associated with a symptomatic secondary block in fatty acid oxidation.
The mitochondrial oxidative phosphorylation and fatty acid oxidation pathways have traditionally been considered independent major sources of cellular energy production; however, case reports of patients with specific enzymatic defects in either pathway have suggested the potential for a complex interference between the two. This study documents a new site of interference between the two pathways, a site in respiratory complex II capable of producing clinical signs of a block in fatty acid oxidation and reduced in vitro activity of acyl-CoA dehydrogenases. The initial patient, and later her newborn sibling, had mildly dysmorphic features, lactic acidosis and a defect in mitochondrial respiratory complex II associated with many biochemical features of a block in fatty acid oxidation. Results of in vitro probing of intact fibroblasts from both patients with methyl[2H3]palmitate and L-carnitine revealed greatly increased [2H3]butyrylcarnitine; however, the ratio of dehydrogenase activity with butyryl-CoA with anti-MCAD inactivating antibody (used to reveal SCAD-specific activity) to that with octanoyl-CoA was normal, excluding a selective SCAD or MCAD deficiency. Respiratory complex II was defective in both patients, with an absent thenoyltrifluoroacetone-sensitive succinate Q reductase activity that was partially restored by supplementation with duroquinone. Although secondary, the block in fatty acid oxidation was a major management problem since attempts to provide essential fatty acids precipitated acidotic decompensations. This study reinforces the need to pursue broadly the primary genetic defect within these two pathways, making full use of increasingly available functional and molecular diagnostic tools.
Gargus
J J
JJ
Department of Physiology and Biophysics, University of California, Irvine, Irvine, CA 92697-4034, USA. jjgargus@uci.edu
Boyle
K
K
Bocian
M
M
Roe
D S
DS
Vianey-Saban
C
C
Roe
C R
CR
D000140:Acidosis, Lactic / Q000151:congenital; D042964:Acyl-CoA Dehydrogenase / Q000172:deficiency / Q000378:metabolism; D001519:Behavior; D001639:Bicarbonates / Q000097:blood; D002331:Carnitine / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D002460:Cell Line; D005227:Fatty Acids / Q000378:metabolism*; D005260:Female; D005347:Fibroblasts / Q000201:enzymology; D006128:Growth / Q000502:physiology; D006801:Humans; D007231:Infant, Newborn; D019344:Lactic Acid / Q000097:blood; D028361:Mitochondrial Diseases / Q000178:diet therapy / Q000235:genetics* / Q000378:metabolism*; D010084:Oxidation-Reduction; D010085:Oxidative Phosphorylation; D010641:Phenotype
D001639:Bicarbonates; D005227:Fatty Acids; C116917:acylcarnitine; D019344:Lactic Acid; D042964:Acyl-CoA Dehydrogenase; D002331:Carnitine